Search Results

Displaying Results 1-7 of 7 "'CMPX'"

Jun 30, 2026, 09:00 ET A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

NK-cell, immune-engager, and AI-discovery approaches include Nkarta (NASDAQ: NKTX), Fate Therapeutics (NASDAQ: FATE), Compass Therapeutics (NASDAQ: CMPX), and Recursion (NASDAQ: RXRX), each distinct, and none a proxy for GT Biopharma.Putting AI to Work on the Hardest Part of Drug DesignThe

More news about: USA News Group


May 21, 2026, 15:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or

More news about: Pomerantz LLP


May 14, 2026, 23:01 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX).  Such investors are advised to contact Danielle Peyton at [email protected] or

More news about: Pomerantz LLP


May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX).  Such investors are advised to contact Danielle Peyton at [email protected] or

More news about: Pomerantz LLP


Apr 30, 2026, 19:42 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX).  Such investors are advised to contact Danielle Peyton at [email protected] or

More news about: Pomerantz LLP


Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

companies, such as TransThera Sciences (HKG: 2617), AstraZeneca (LON: AZN), J-Pharma, OHARA Pharmaceutical (TYO: 5218), Compass Therapeutics (NASDAQ: CMPX), Merck (NYSE: MRK), Eisai (TYO: 4523), Seagen (NASDAQ: SGEN), Pfizer (NYSE: PFE), Bold Therapeutics (NASDAQ: BOLD), Senhwa Biosciences, Virogin Biotech,

More news about: DelveInsight Business Research, LLP


Feb 04, 2026, 17:00 ET Bélanger Celebrates 60 Years of Design Excellence

60th anniversary at The Canadian Mechanical and Plumbing Expo (CMPX) with an interactive booth experience and the unveiling of a limited-edition faucet, offering show attendees a first look at what's next for Bélanger. CMPX 2026 takes place March 25–27, 2026, at the Metro Toronto

More news about: Bélanger


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.